Tradestie Institutional Equity Comparison Engine
CGEM vs EDIT โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CGEM Overall Edge
CGEM Captures Institutional Edge (4โ0 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Cullinan Therapeutics, Inc. Common Stock (CGEM) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, CGEM trades at 6.7x Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus EDIT at N/M Forward P/E and -167.0% operating margin (+37.4% YoY). In options structure, CGEM sits in UNCLASSIFIED (9th %ile IV; Dealer Gamma Walls on Pro) against EDIT sits in BREAKDOWN (38th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
CGEM
CGEM 6.7x vs EDIT N/M Fwd P/E
Growth & Margin Winner
CGEM
Op Margin 0.0% vs -167.0% ยท YoY +0.0% vs +37.4%
Momentum & Technical Winner
CGEM
1Y +17.5% vs -25.0% ยท 52W Pos 12% vs 11%
Options & Structure Winner
CGEM
UNCLASSIFIED (9th %ile IV) vs BREAKDOWN (38th %ile IV)
CGEM
NASDAQ
Cullinan Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$9.72
-5.45% 1D
Market Cap
$653.8M
1M Return
-24.83%
1Y Return
+17.53%
Forward P/E
6.7x
Unified AI Score
41.0 / 100
SELL
Tech 25.0
Fund 51.0
Flow 50.0
Mom 59.0
EDIT
NASDAQ
Editas Medicine, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.91
-12.21% 1D
Market Cap
$336.5M
1M Return
-18.94%
1Y Return
-25.0%
Forward P/E
N/M
Unified AI Score
48.4 / 100
HOLD
Tech 33.0
Fund 55.0
Flow 69.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CGEM +17.53%
EDIT -25.0%
Spread: +42.53 pp (CGEM Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
CGEM TTM Op. Margin: 0.0%
EDIT TTM Op. Margin: -167.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CGEM vs EDIT. Trailing 12-month operating profitability (CGEM 0.0% vs EDIT -167.0%) and valuation multiples (CGEM 6.7x vs EDIT N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CGEM | EDIT | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $653.8M | $336.5M | Larger Scale | CGEM |
| Trailing P/E Ratio Valuation | 6.7x | N/M | Lower Multiple | CGEM |
| Forward P/E Ratio Valuation | 6.7x | N/M | Lower Multiple | CGEM |
| Revenue Growth (YoY) Growth | +0.0% | +37.4% | Higher Growth | EDIT |
| Operating Margin (TTM) Profitability | 0.0% | -167.0% | Higher Margin | CGEM |
| Net Profit Margin Profitability | 0.0% | -144.9% | Higher Margin | CGEM |
| Return on Equity (ROE) Capital Efficiency | -50.3% | -147.4% | Higher ROE | CGEM |
| 52-Week Range Position Momentum | 12% ($8โ$23) | 11% ($2โ$4) | Stronger Trend | CGEM |
| Beta / 30D Volatility Risk Regime | 1.56ฮฒ ยท 104% Vol | 2.32ฮฒ ยท 102% Vol | Lower Realized Risk | EDIT |
| Unified Institutional Score Composite Signal | 41.0 / 100 (SELL) | 48.4 / 100 (HOLD) | Higher Composite | EDIT |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CGEM vs EDIT Buy Guide
CGEM
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
9th %ile
IV Regime
Compressed (<25th %ile)
EDIT
BREAKDOWN
146d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
38th %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CGEM nor EDIT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.